/PRNewswire/ AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of.
Divestment of DSUVIA® to Alora Pharmaceuticals expected to close the week of April 3, 2023 AcelRx advancing its proprietary Niyad™ nafamastat program with FDA.
New York, NY (PRWEB) March 28, 2023 NEW YORK, NY, March 28, 2023 – The American Parkinson Disease Association (APDA) officially announces the 2023 schedule